Carey O’Connor Kolaja's most recent trade in Revance Therapeutics Inc was a trade of 23,458 Stock Option (Right to buy) done . Disclosure was reported to the exchange on May 1, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Revance Therapeutics Inc | Carey O’Connor Kolaja | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 23,458 | 23,458 | - | - | Stock Option (Right to buy) | |
| Revance Therapeutics Inc | Carey O’Connor Kolaja | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 15,000 | 31,561 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Carey O’Connor Kolaja | Director | Sale of securities on an exchange or to another person at price $ 28.24 per share. | 15 Jun 2023 | 2,500 | 16,561 (0%) | 0% | 28.2 | 70,600 | Common Stock |
| Revance Therapeutics Inc | Carey O’Connor Kolaja | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2023 | 2,500 | 8,256 | - | - | Stock Option (Right to buy) | |
| Revance Therapeutics Inc | Carey O’Connor Kolaja | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.12 per share. | 15 Jun 2023 | 2,500 | 19,061 (0%) | 0% | 18.1 | 45,300 | Common Stock |
| Revance Therapeutics Inc | Carey O’Connor Kolaja | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 5,915 | 5,915 | - | - | Stock Option (Right to buy) | |
| Revance Therapeutics Inc | Carey O’Connor Kolaja | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 3,534 | 16,561 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Carey O’Connor Kolaja | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 10,756 | 10,756 | - | - | Stock Option (Right to buy) | |
| Revance Therapeutics Inc | Carey O’Connor Kolaja | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 1,268 | 1,268 | - | - | Stock Option (Right to buy) | |
| Revance Therapeutics Inc | Carey O’Connor Kolaja | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 674 | 6,968 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Carey O’Connor Kolaja | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 11,417 | 11,417 | - | - | Stock Option (Right to buy) | |
| Revance Therapeutics Inc | Carey O’Connor Kolaja | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 6,294 | 6,294 (0%) | 0% | 0 | Common Stock |